Vesalius Biocapital Partners

Inflammatix develops rapid molecular diagnostics tests that interpret the immune system to resolve major clinical challenges. Initially focused on acute bacterial and viral infections, sepsis, and other conditions like tropical infections and autoimmune diseases.

Caresyntax develops a digital surgery platform that improves patient outcomes by analyzing large volumes of data from operating rooms. Its proprietary software and AI enable OR teams to predict and enhance surgical performance, helping surgeons benchmark their care, hospital administrators optimize resources, medical device companies advance products, and insurance providers assess risk.

Catalym GmbH, established in Munich, Germany in 2016, is a biotechnology company dedicated to developing innovative immunotherapies for cancer patients. The company focuses on neutralizing GDF-15, a central regulator of the immune system in the tumor microenvironment, aiming to demonstrate clinical proof-of-concept across multiple solid tumor indications with its lead program CTL-002. Catalym's mission is to transform cancer patients' lives by engaging their own immune systems and improving treatment options.

HepaRegeniX GmbH is a biopharmaceutical company based in Ulm, Germany, founded in 2016. It specializes in developing innovative therapies for acute and chronic liver diseases, focusing on restoring the regenerative capacity of hepatocytes. The company’s therapeutic approach is based on research led by Professor Lars Zender at the University Hospital Tübingen, which identified mitogen-activated protein kinase kinase 4 (MKK4) as a critical regulator of liver regeneration. HepaRegeniX is developing small-molecule inhibitors of MKK4, aiming to enhance liver regeneration even in severely diseased conditions. The company’s potential treatments may address various liver disorders, including nonalcoholic steatohepatitis.

inHEART specializes in AI-driven software for medical image analysis and cardiac modeling. It creates digital twins of patients' hearts to enhance diagnosis, therapy planning, and navigation for heart rhythm disorders.

Cognivia is a company that focuses on developing analytical tools aimed at optimizing and accelerating the clinical development of new medicines. Its innovative tools employ predictive techniques to enhance the clinical evaluation of drugs and other therapeutics. By addressing and mitigating the variability in clinical trial data, Cognivia enables its clients to identify and manage critical sources of variability, ultimately improving the efficiency and effectiveness of clinical trials.

Tonic App S.A. is a mobile application developer based in Porto, Portugal, founded in 2016. The company’s flagship application serves as a comprehensive platform for medical professionals, facilitating communication, collaboration, and information sharing among doctors. It enables users to message, share, and archive patient cases, seek expert advice, and network with peers. Tonic App is also utilized by hospitals, pharmaceutical and medical technology firms, as well as medical associations, to connect with healthcare professionals and disseminate relevant medical content. The application supports various functionalities including video consultations, clinical decision tools, and the sharing of medical images, thereby enhancing clinical work efficiency and improving patient outcomes. It is accredited as an e-library by the European Accreditation Council in CME, underscoring its commitment to quality and safety in clinical practices.

Memo Therapeutics AG is a Swiss biotechnology company based in Basel, specializing in antibody discovery and immune repertoire analysis. The company has developed the MemoMAB platform, which generates a recombinant in vitro copy of an individual’s B cell or antibody repertoire, creating a comprehensive library of unique antibodies. This innovative technology allows for the identification of a vast array of relevant and rare antibodies, significantly enhancing the potential for immune repertoire analysis and antibody discovery. Memo Therapeutics aims to leverage its platform in proprietary antibody lead discovery programs and through collaborations, with a focus on improving treatment options for patients suffering from viral infections and cancer.

Catalym GmbH, established in Munich, Germany in 2016, is a biotechnology company dedicated to developing innovative immunotherapies for cancer patients. The company focuses on neutralizing GDF-15, a central regulator of the immune system in the tumor microenvironment, aiming to demonstrate clinical proof-of-concept across multiple solid tumor indications with its lead program CTL-002. Catalym's mission is to transform cancer patients' lives by engaging their own immune systems and improving treatment options.

Scenic Biotech develops genomics and immunotherapy technologies to unlock genetic suppressors as new drug targets for cancer and rare genetic diseases. The company focuses on disease suppressing genes that can counteract disease-causing mutations, enabling rapid identification and validation of novel targets for medicines. By leveraging genomics to identify modifiers that suppress or block the effects of harmful genes, Scenic Biotech aims to create disease-modifying therapies that address the genetic drivers of severe illnesses.

Memo Therapeutics AG is a Swiss biotechnology company based in Basel, specializing in antibody discovery and immune repertoire analysis. The company has developed the MemoMAB platform, which generates a recombinant in vitro copy of an individual’s B cell or antibody repertoire, creating a comprehensive library of unique antibodies. This innovative technology allows for the identification of a vast array of relevant and rare antibodies, significantly enhancing the potential for immune repertoire analysis and antibody discovery. Memo Therapeutics aims to leverage its platform in proprietary antibody lead discovery programs and through collaborations, with a focus on improving treatment options for patients suffering from viral infections and cancer.

Rejuvenate Biomed is a biomedical company dedicated to researching the biology of aging. It applies this knowledge to identify safe and well-tolerated drugs that maintain and restore natural cell resilience, improving responses to age-related diseases.

Caresyntax develops a digital surgery platform that improves patient outcomes by analyzing large volumes of data from operating rooms. Its proprietary software and AI enable OR teams to predict and enhance surgical performance, helping surgeons benchmark their care, hospital administrators optimize resources, medical device companies advance products, and insurance providers assess risk.

Topas Therapeutics GmbH, established in 2013 and based in Hamburg, Germany, is a biotechnology company specializing in the development of nanoparticle-based therapeutics. The company's core focus is to induce antigen-specific immune tolerance, utilizing the liver's natural immunology capabilities to treat autoimmune diseases, allergies, and anti-drug antibodies. Topas' proprietary platform, Topas Particle Conjugates, targets liver sinusoidal endothelial cells, enabling tolerance against blood-borne antigens. The company has several clinical-stage programs, including TPM203 for pemphigus vulgaris, and collaborations with pharmaceutical giants like Eli Lilly and Boehringer Ingelheim. Topas Therapeutics is backed by prominent investors such as Epidarex Capital, Gimv, EMBL Ventures, Evotec, and Boehringer Ingelheim Venture Fund.

Rejuvenate Biomed is a biomedical company dedicated to researching the biology of aging. It applies this knowledge to identify safe and well-tolerated drugs that maintain and restore natural cell resilience, improving responses to age-related diseases.

Sword Health specializes in digital health solutions for physical rehabilitation. It employs artificial intelligence to deliver personalized care globally, enabling patients to perform interactive exercises at home under remote physiotherapist supervision.

Catalym GmbH, established in Munich, Germany in 2016, is a biotechnology company dedicated to developing innovative immunotherapies for cancer patients. The company focuses on neutralizing GDF-15, a central regulator of the immune system in the tumor microenvironment, aiming to demonstrate clinical proof-of-concept across multiple solid tumor indications with its lead program CTL-002. Catalym's mission is to transform cancer patients' lives by engaging their own immune systems and improving treatment options.

Topas Therapeutics GmbH, established in 2013 and based in Hamburg, Germany, is a biotechnology company specializing in the development of nanoparticle-based therapeutics. The company's core focus is to induce antigen-specific immune tolerance, utilizing the liver's natural immunology capabilities to treat autoimmune diseases, allergies, and anti-drug antibodies. Topas' proprietary platform, Topas Particle Conjugates, targets liver sinusoidal endothelial cells, enabling tolerance against blood-borne antigens. The company has several clinical-stage programs, including TPM203 for pemphigus vulgaris, and collaborations with pharmaceutical giants like Eli Lilly and Boehringer Ingelheim. Topas Therapeutics is backed by prominent investors such as Epidarex Capital, Gimv, EMBL Ventures, Evotec, and Boehringer Ingelheim Venture Fund.

Sword Health specializes in digital health solutions for physical rehabilitation. It employs artificial intelligence to deliver personalized care globally, enabling patients to perform interactive exercises at home under remote physiotherapist supervision.

Founded by experts in DNA sequencing and diagnostic analyses in oncology, OncoDNA offers precision medicine solutions for cancer treatment. It provides clinical guidance for late-stage patients, supports research, and aids drug development.

Mecuris GmbH, founded in 2016 and based in Munich, Germany, specializes in the development and supply of customized orthopedic aids. The company's product range includes orthoses, prostheses, and related equipment, with notable offerings such as Mecuris FirStep, Mecuris NexStep, Mecuris cover, and the Mecuris Solution Platform. Mecuris aims to revolutionize the orthotics and prosthetics (O&P) industry by leveraging digital technology and 3D printing. Their platform uses patient data and scans to semi-automatically create individualized 3D designs for patient aids, which can be printed locally. This approach significantly reduces production times, enabling a fully customized fit, functionality, and appearance for wearers. Mecuris collaborates with O&P professionals to co-create these custom products, enhancing the lives of patients through innovative digital solutions.

Tonic App S.A. is a mobile application developer based in Porto, Portugal, founded in 2016. The company’s flagship application serves as a comprehensive platform for medical professionals, facilitating communication, collaboration, and information sharing among doctors. It enables users to message, share, and archive patient cases, seek expert advice, and network with peers. Tonic App is also utilized by hospitals, pharmaceutical and medical technology firms, as well as medical associations, to connect with healthcare professionals and disseminate relevant medical content. The application supports various functionalities including video consultations, clinical decision tools, and the sharing of medical images, thereby enhancing clinical work efficiency and improving patient outcomes. It is accredited as an e-library by the European Accreditation Council in CME, underscoring its commitment to quality and safety in clinical practices.

Founded in 2013, Forendo Pharma is a Finnish biopharmaceutical company specializing in drug discovery and development. It focuses on tissue-specific regulation of sex hormone effects to treat urological and gynecological conditions. Key products include Fispemifene for low testosterone symptoms in men and a 17HSD1-inhibitor for endometriosis.

DEARHealth is a health technology company based in Beverly Hills, California, founded in 2013. It specializes in developing a Software as a Service (SaaS) based healthcare management platform tailored for medical providers and health insurers. The company leverages advanced data analytics to create disease-specific, coordinated care pathways that enhance provider workflows, support organizational decision-making, and engage patients through dedicated apps. DEARHealth's solutions are designed to improve health outcomes and experiences for chronically ill patients while reducing costs, with a focus on value-based healthcare.

Mecuris GmbH, founded in 2016 and based in Munich, Germany, specializes in the development and supply of customized orthopedic aids. The company's product range includes orthoses, prostheses, and related equipment, with notable offerings such as Mecuris FirStep, Mecuris NexStep, Mecuris cover, and the Mecuris Solution Platform. Mecuris aims to revolutionize the orthotics and prosthetics (O&P) industry by leveraging digital technology and 3D printing. Their platform uses patient data and scans to semi-automatically create individualized 3D designs for patient aids, which can be printed locally. This approach significantly reduces production times, enabling a fully customized fit, functionality, and appearance for wearers. Mecuris collaborates with O&P professionals to co-create these custom products, enhancing the lives of patients through innovative digital solutions.

OMEICOS Therapeutics is a Berlin-based biotechnology company developing small molecule therapeutics to prevent and treat cardiovascular and ophthalmic diseases. The company uses synthetic analogues of Epoxyeicosanoids, metabolites of omega-3 fatty acids, to activate anti-inflammatory, anti-arrhythmic, and cardioprotective pathways in heart cells. Its approach leverages endogenous cardio-protective signaling to stabilize heart rhythm and potentially mitigate electrical and structural remodeling of diseased myocardium.

Founded in 2013, Forendo Pharma is a Finnish biopharmaceutical company specializing in drug discovery and development. It focuses on tissue-specific regulation of sex hormone effects to treat urological and gynecological conditions. Key products include Fispemifene for low testosterone symptoms in men and a 17HSD1-inhibitor for endometriosis.

Sword Health specializes in digital health solutions for physical rehabilitation. It employs artificial intelligence to deliver personalized care globally, enabling patients to perform interactive exercises at home under remote physiotherapist supervision.

Ncardia develops predictive human cellular assay systems based on human induced pluripotent stem cells (hiPSCs) to support safety and efficacy testing of drug candidates and enhance cardiovascular and neural drug screening. By producing hiPSC-derived models that reflect human disease biology, the company helps researchers and drug developers better predict human responses, streamline preclinical evaluation, and accelerate the discovery and development of new therapies.

OMEICOS Therapeutics is a Berlin-based biotechnology company developing small molecule therapeutics to prevent and treat cardiovascular and ophthalmic diseases. The company uses synthetic analogues of Epoxyeicosanoids, metabolites of omega-3 fatty acids, to activate anti-inflammatory, anti-arrhythmic, and cardioprotective pathways in heart cells. Its approach leverages endogenous cardio-protective signaling to stabilize heart rhythm and potentially mitigate electrical and structural remodeling of diseased myocardium.

Founded in 2003, Exact Imaging specializes in developing high-resolution micro-ultrasound systems for real-time imaging and guided biopsies, primarily focused on the urological market for prostate cancer detection. Its flagship product, ExactVu™, operates at 29 MHz, offering unmatched resolution for visualizing and targeting suspicious regions, while also facilitating systematic TRUS biopsies.

Promethera Biosciences is a clinical-stage biopharmaceutical company focused on developing innovative therapies for liver diseases. Founded in 2009 and based in Mont-Saint-Guibert, Belgium, with an office in Tokyo, Japan, the company specializes in cell therapy products, notably HepaStem and H2Stem, which utilize allogeneic progenitor cells derived from healthy human adult livers. Promethera is actively working on treatments for a range of conditions, including acute-on-chronic liver failure, hemophilia, liver fibrosis, non-alcoholic steatohepatitis, liver-based metabolic diseases, and urea cycle disorders. The company also engages in strategic alliances to further its research and development efforts, enhancing its capacity to discover and commercialize effective cell therapies for liver-related ailments.

Ogeda SA is a clinical-stage drug discovery company based in Gosselies, Belgium, that specializes in the invention and development of small molecule drugs targeting G-Protein Coupled Receptors (GPCRs). Founded in 1994 and formerly known as Euroscreen, the company focuses on developing innovative therapies for women's health disorders, with its lead product, fezolinetant, currently in Phase II clinical development. In addition to fezolinetant, Ogeda is advancing other small molecules aimed at treating various endocrine, central nervous system, and inflammatory conditions. The company maintains facilities in Brussels and Paris, and operates as a subsidiary of Astellas Pharma Inc. Through its research, Ogeda seeks to provide effective treatment options for hormone-dependent pathologies and other related health issues.

Apitope is a biotechnology company dedicated to discovering and developing disease-modifying therapies for autoimmune and allergic diseases. Its research primarily targets conditions such as multiple sclerosis, Graves’ disease, Factor VIII intolerance, and uveitis. Utilizing a proprietary platform technology, Apitope develops antigen-specific therapeutic peptides aimed at addressing the underlying causes of these diseases. The company’s innovative approach seeks to enhance patients' quality of life by providing treatments that minimize the risk of secondary infections and complications. Apitope's first product candidate has been licensed to a major pharmaceutical partner, Merck Serono, while the company continues to advance its remaining portfolio of therapeutic candidates.

OMEICOS Therapeutics is a Berlin-based biotechnology company developing small molecule therapeutics to prevent and treat cardiovascular and ophthalmic diseases. The company uses synthetic analogues of Epoxyeicosanoids, metabolites of omega-3 fatty acids, to activate anti-inflammatory, anti-arrhythmic, and cardioprotective pathways in heart cells. Its approach leverages endogenous cardio-protective signaling to stabilize heart rhythm and potentially mitigate electrical and structural remodeling of diseased myocardium.

Genkyotex SA is a biopharmaceutical company focused on developing innovative oral small molecule therapies that selectively inhibit NOX enzymes involved in various disease processes, including fibrosis, inflammation, pain, cancer, and neurodegeneration. Its lead candidate, GKT831, targets NOX1 and NOX4 and is currently undergoing Phase II clinical trials for primary biliary cholangitis and type 1 diabetes-related kidney disease. Additionally, Genkyotex is advancing a preclinical candidate, GKT771, which inhibits NOX1 and aims to address pain processing and inflammation. The company also holds a license agreement with the Serum Institute of India for GTL003, an antigen intended for developing combination vaccines against infectious diseases. Established in 2006 and headquartered in Labège, France, Genkyotex is committed to improving treatment options for chronic diseases through its novel therapeutic approaches.

Humedics develops a breath analysis device that measures liver function in real-time. Its LiMAx test enables clinicians to quantitatively determine individual liver function capacity, supporting treatment decisions and improving patient outcomes. The company focuses on applications such as liver transplantation diagnosis, living donor assessment, and disease evaluation.

Ncardia develops predictive human cellular assay systems based on human induced pluripotent stem cells (hiPSCs) to support safety and efficacy testing of drug candidates and enhance cardiovascular and neural drug screening. By producing hiPSC-derived models that reflect human disease biology, the company helps researchers and drug developers better predict human responses, streamline preclinical evaluation, and accelerate the discovery and development of new therapies.

Trod Medical S.A. is a medical device manufacturer founded in 2006, with its headquarters located in Leuven, Belgium, and a presence in the Tampa Bay area, USA. The company specializes in innovative ablation technologies, particularly in the development of radiofrequency (RF) ablation devices. Trod Medical's flagship product, the EncageTM, is a percutaneous RF device designed to ablate soft tissues with exceptional precision, significantly reducing collateral damage compared to conventional treatments. This advancement is particularly relevant in the treatment of prostate cancer, a prevalent condition that affects around 240,000 new patients annually in the United States. The company aims to address the limitations of existing therapies, which often lead to serious side effects such as erectile dysfunction and urinary incontinence. Through its focus on focal ablation techniques, Trod Medical is committed to improving patient outcomes and enhancing surgical efficacy.

Complix is a biopharmaceutical company dedicated to the discovery and development of Alphabodies™, a novel class of therapeutics that provide distinct advantages over traditional protein-based treatments. These Alphabodies™ exhibit high affinity binding to a diverse array of disease targets, particularly those that are challenging for conventional antibodies to access. The company focuses on developing its pipeline of Alphabody therapeutics to address intracellular disease targets integral to conditions such as cancer, autoimmunity, and viral diseases. By merging the targeted potency of biologics with the stability and cell-penetrating capabilities of small molecules, Complix aims to overcome the limitations associated with conventional antibodies and small molecule drugs, thereby providing innovative solutions for patients facing intractable health issues.

FF Pharma is a biopharmaceutical company focused on developing innovative therapies for chronic inflammatory diseases, specifically targeting conditions such as primary biliary cirrhosis and Crohn’s disease. The company is advancing an anti-CD40 monoclonal antibody therapy that acts as a negative allosteric modulator of the CD40 pathway. This therapy serves as a reversible switch for B cell activation, inhibiting aberrant immune responses associated with autoimmune diseases. By targeting the CD40 pathway, FF Pharma aims to provide effective treatment options for patients suffering from chronic inflammation and related disorders.

Ogeda SA is a clinical-stage drug discovery company based in Gosselies, Belgium, that specializes in the invention and development of small molecule drugs targeting G-Protein Coupled Receptors (GPCRs). Founded in 1994 and formerly known as Euroscreen, the company focuses on developing innovative therapies for women's health disorders, with its lead product, fezolinetant, currently in Phase II clinical development. In addition to fezolinetant, Ogeda is advancing other small molecules aimed at treating various endocrine, central nervous system, and inflammatory conditions. The company maintains facilities in Brussels and Paris, and operates as a subsidiary of Astellas Pharma Inc. Through its research, Ogeda seeks to provide effective treatment options for hormone-dependent pathologies and other related health issues.

Genkyotex SA is a biopharmaceutical company focused on developing innovative oral small molecule therapies that selectively inhibit NOX enzymes involved in various disease processes, including fibrosis, inflammation, pain, cancer, and neurodegeneration. Its lead candidate, GKT831, targets NOX1 and NOX4 and is currently undergoing Phase II clinical trials for primary biliary cholangitis and type 1 diabetes-related kidney disease. Additionally, Genkyotex is advancing a preclinical candidate, GKT771, which inhibits NOX1 and aims to address pain processing and inflammation. The company also holds a license agreement with the Serum Institute of India for GTL003, an antigen intended for developing combination vaccines against infectious diseases. Established in 2006 and headquartered in Labège, France, Genkyotex is committed to improving treatment options for chronic diseases through its novel therapeutic approaches.

Trinean is a Belgium-based technology provider specializing in micro-volume molecular spectroscopy. Founded in 2006 as a spin-out from Ghent University and Imec Leuven, the company develops UV/VIS spectrometers for biomolecule quantification. Their flagship products, the DropSense™16 and DropSense™96, analyze up to 16 and 96 samples respectively, utilizing microfluidic chips for standardized sample analysis through DropPlates™ and Slides. Trinean's platform is enhanced with a software toolbox designed to improve data interpretation and lab automation, catering to the needs of biologics researchers.

Amakem is a biopharmaceutical company specializing in ophthalmology. It focuses on developing treatments for serious eye conditions using its proprietary 'Localized Drug Action' platform, aiming to create safe and effective kinase inhibitors with minimal systemic exposure.

ProFibrix B.V. is a biotechnology company focused on developing and marketing innovative products for the hemostasis and regenerative medicine sectors. Founded in 2004, the company specializes in Fibrocaps, a dry powder topical hemostat and tissue sealant designed to effectively control acute and severe bleeding during surgical procedures or due to traumatic injuries. Fibrocaps is formulated from a blend of fibrinogen and thrombin, two key proteins vital for blood clotting and tissue repair. Additionally, ProFibrix offers a sterilized single-use delivery device that facilitates the application of Fibrocaps to targeted areas, minimizing the need to manipulate the wound in a surgical setting. The company's products leverage human fibrinogen, a natural blood protein, to enhance hemostatic efficacy and promote healing.

Genkyotex SA is a biopharmaceutical company focused on developing innovative oral small molecule therapies that selectively inhibit NOX enzymes involved in various disease processes, including fibrosis, inflammation, pain, cancer, and neurodegeneration. Its lead candidate, GKT831, targets NOX1 and NOX4 and is currently undergoing Phase II clinical trials for primary biliary cholangitis and type 1 diabetes-related kidney disease. Additionally, Genkyotex is advancing a preclinical candidate, GKT771, which inhibits NOX1 and aims to address pain processing and inflammation. The company also holds a license agreement with the Serum Institute of India for GTL003, an antigen intended for developing combination vaccines against infectious diseases. Established in 2006 and headquartered in Labège, France, Genkyotex is committed to improving treatment options for chronic diseases through its novel therapeutic approaches.

Activaero develops controlled breathing technologies for efficient pulmonary delivery of inhaled therapeutics. Its flagship product, AKITA, uses smart card technology to enable safe and precise local drug deposition in the lungs, targeting conditions such as asthma, COPD, cystic fibrosis, and idiopathic pulmonary fibrosis.

Complix is a biopharmaceutical company dedicated to the discovery and development of Alphabodies™, a novel class of therapeutics that provide distinct advantages over traditional protein-based treatments. These Alphabodies™ exhibit high affinity binding to a diverse array of disease targets, particularly those that are challenging for conventional antibodies to access. The company focuses on developing its pipeline of Alphabody therapeutics to address intracellular disease targets integral to conditions such as cancer, autoimmunity, and viral diseases. By merging the targeted potency of biologics with the stability and cell-penetrating capabilities of small molecules, Complix aims to overcome the limitations associated with conventional antibodies and small molecule drugs, thereby providing innovative solutions for patients facing intractable health issues.

Promethera Biosciences is a clinical-stage biopharmaceutical company focused on developing innovative therapies for liver diseases. Founded in 2009 and based in Mont-Saint-Guibert, Belgium, with an office in Tokyo, Japan, the company specializes in cell therapy products, notably HepaStem and H2Stem, which utilize allogeneic progenitor cells derived from healthy human adult livers. Promethera is actively working on treatments for a range of conditions, including acute-on-chronic liver failure, hemophilia, liver fibrosis, non-alcoholic steatohepatitis, liver-based metabolic diseases, and urea cycle disorders. The company also engages in strategic alliances to further its research and development efforts, enhancing its capacity to discover and commercialize effective cell therapies for liver-related ailments.

Activaero develops controlled breathing technologies for efficient pulmonary delivery of inhaled therapeutics. Its flagship product, AKITA, uses smart card technology to enable safe and precise local drug deposition in the lungs, targeting conditions such as asthma, COPD, cystic fibrosis, and idiopathic pulmonary fibrosis.

Apitope is a biotechnology company dedicated to discovering and developing disease-modifying therapies for autoimmune and allergic diseases. Its research primarily targets conditions such as multiple sclerosis, Graves’ disease, Factor VIII intolerance, and uveitis. Utilizing a proprietary platform technology, Apitope develops antigen-specific therapeutic peptides aimed at addressing the underlying causes of these diseases. The company’s innovative approach seeks to enhance patients' quality of life by providing treatments that minimize the risk of secondary infections and complications. Apitope's first product candidate has been licensed to a major pharmaceutical partner, Merck Serono, while the company continues to advance its remaining portfolio of therapeutic candidates.

Trinean is a Belgium-based technology provider specializing in micro-volume molecular spectroscopy. Founded in 2006 as a spin-out from Ghent University and Imec Leuven, the company develops UV/VIS spectrometers for biomolecule quantification. Their flagship products, the DropSense™16 and DropSense™96, analyze up to 16 and 96 samples respectively, utilizing microfluidic chips for standardized sample analysis through DropPlates™ and Slides. Trinean's platform is enhanced with a software toolbox designed to improve data interpretation and lab automation, catering to the needs of biologics researchers.

Genomic Vision is a biotechnology company specializing in molecular diagnostics and technology. It utilizes its proprietary Molecular Combing technology, which allows for the detection of single DNA molecules, to develop and commercialize innovative genetic tests and research tools. The company's products are primarily focused on DNA analysis and genetic testing, addressing areas such as cancer, rare inherited disorders, and pharmacogenomics. Through its advancements in biomarker discovery and DNA detection, Genomic Vision aims to enhance research capabilities and improve clinical outcomes in the life sciences sector.